TreeFrog Therapeutics
TreeFrog Therapeutics is a French biotech developing iPSC-derived cell therapies through its proprietary C-Stem™ biomimetic encapsulation platform, enabling commercial-scale GMP cell manufacturing. It serves large-pharma partners via technology licensing and co-development, and advances a proprietary pipeline led by TFG-001 for Parkinson's disease.
- Company typePrivate
- Founded2018
- HeadquartersBordeaux, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What TreeFrog Therapeutics does
TreeFrog Therapeutics is a French regenerative-medicine biotech founded in December 2018 in Bordeaux, with operations now spanning France (Pessac HQ), the United States (Boston), and Japan (Kobe). The company operates a dual business model centered on its proprietary C-Stem™ technology platform — a biomimetic 3D encapsulation system capable of generating over 1,000 GMP-compliant capsules per second and producing 15 billion iPSC-derived cells in a single 10-liter bioreactor batch, achieving 275-300x expansion in 6-7 days while preserving 100% genomic integrity. On one leg, TreeFrog develops a proprietary cell-therapy pipeline led by TFG-001, a 3D neural microtissue for Parkinson's disease (preclinical, first-in-human planned for 2026, CTA filing 2027), and a discovery-stage liver disease program. On the other leg, it out-licenses the C-Stem™ platform to large-pharma and biotech partners — including Vertex Pharmaceuticals (Type 1 Diabetes), Umoja Biopharma (immuno-oncology), GAIA BioMedicine (NK cells), and Bristol-Myers Squibb (strategic investor and partner).
The company generates revenue through technology licensing and royalties, strategic co-development arrangements, and research services to academic institutions. Its customer base is highly concentrated in pharmaceutical and biotech companies seeking scalable cell-therapy manufacturing, with secondary engagement of academic medical centers for research-grade iPS cell supply. To date, TreeFrog has raised approximately $82M in equity (including a $75M Series B in September 2021 led by Bpifrance Large Venture) and €30M in EIB debt financing (May 2025), supplemented by over €3M in non-dilutive grants from Horizon 2020 and Bpifrance. As of 2025-2026, the company is navigating a strategic reorganization (PSE, September 2025) and leadership transition (Mark Rothera appointed CEO December 2025) while preparing its lead asset for clinical entry.
TreeFrog Therapeutics firmographics
Firmographics- Name
- TreeFrog Therapeutics
- Legal name
- TreeFrog Therapeutics
- Website
- https://treefrog.fr
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- TreeFrog Therapeutics is a French biotech developing iPSC-derived cell therapies through its proprietary C-Stem™ biomimetic encapsulation platform, enabling commercial-scale GMP cell manufacturing. It serves large-pharma partners via technology licensing and co-development, and advances a proprietary pipeline led by TFG-001 for Parkinson's disease.
- Ownership category
- akta.pro rank
TreeFrog Therapeutics industry classification
Industry- Product category
- Regenerative Medicine Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where TreeFrog Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Bordeaux
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
TreeFrog Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Proprietary Cell Therapy Pipeline: Developing proprietary pipeline of iPSC-derived cell therapies with lead program TFG-001 for Parkinson's disease and discovery program for liver disease. First-in-human trial planned for 2026.
- C-Stem™ Technology Licensing: Out-licensing C-Stem technology platform to pharmaceutical partners including exclusive and non-exclusive arrangements for cell therapy manufacturing
- Strategic Partnerships & Co-development: Co-development arrangements with pharmaceutical companies such as Vertex (Type 1 Diabetes) and others for optimized cell therapy production using C-Stem platform
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
TreeFrog Therapeutics product offering
Product offeringCore offering
TreeFrog Therapeutics develops and out-licenses C-Stem™, a proprietary biomimetic 3D cell culture and encapsulation technology platform that enables industrial-scale, GMP-compliant manufacturing of iPSC-derived cell therapies (up to 15 billion cells per batch in 10L bioreactors). The company also internally develops a proprietary pipeline of regenerative medicine cell therapies, with its lead program TFG-001 (3D neural microtissue for Parkinson's disease, first-in-human trial planned for 2026) and a discovery-stage liver disease program.
Product overview
TreeFrog Therapeutics is a regenerative medicine biotech company developing next-generation iPSC-derived cell therapies through its proprietary C-Stem™ technology platform. The platform enables large-scale, GMP-compliant cell manufacturing using biomimetic 3D culture and encapsulation technology. The company's product portfolio includes TFG-001, a 3D neural microtissue cell therapy for Parkinson's disease in late preclinical stage, alongside a discovery program for liver disease. TreeFrog operates a dual business model combining proprietary pipeline development with out-licensing of the C-Stem™ technology to partners.
Differentiator
Problem solved
Functional benefit
Brands
- C-Stem™: Proprietary biomimetic technology platform for mass production of stem cells and cell therapies using 3D encapsulation and bioreactor-based manufacturing
Products and services
- C-Stem™ Technology Platform
Quantifiable outcome
- 275-300x hiPSC expansion within 6-7 days vs industry benchmarks
- +5 more outcomes
Companies that use TreeFrog Therapeutics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
TreeFrog Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TreeFrog Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered strategic and core.
- University of PittsburghstrategicPioneering research collaboration in immuno-oncology to develop next-generation cell therapies using C-Stem technology
- Vertex PharmaceuticalscoreLicense and collaboration agreement to optimize production of Vertex's cell therapies for Type 1 Diabetes using TreeFrog's proprietary C-Stem technology platform
- GAIA BioMedicinestrategicCollaboration for expansion of allogeneic NK-like cells against solid tumors using C-Stem platform, with GAIA being a Japanese clinical-stage company pioneering allogeneic NK-like cell therapies
- Umoja BiopharmastrategicCollaboration to address current challenges in ex vivo allogeneic therapies for immuno-oncology using C-Stem technology platform
- Établissement Français du Sang (EFS)strategicAgreement with French Blood Agency to increase production of hematopoietic stem cell grafts derived from iPS cells
- InvetechcoreExtended partnership to transform high-throughput stem cell encapsulation technology into GMP system for commercial-scale cell therapy manufacturing. Invetech providing GMP encapsulation devices for TreeFrog's programs
- Imagine InstitutecoreFirst customer delivery of 143 million human iPS cells with demonstrated 100% genomic integrity preservation. Leading European center for genetic disease research
- Aquitaine Science Transfert (SATT Aquitaine)coreLicense agreement to industrialize and commercialize breakthrough 3D cell culture technology based on patents from University of Bordeaux, CNRS, and Institut d'Optique Graduate School
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
TreeFrog Therapeutics competitors and assessment
Company assessmentDirect peers
- BlueRock Therapeutics: Bayer-owned clinical-stage iPSC-derived cell therapy company developing a dopaminergic neuron therapy (DA01) for Parkinson's disease — directly comparable to TreeFrog's TFG-001 in indication, modality (iPSC), and disease target, with BlueRock at a more advanced clinical stage.
- Fate Therapeutics: Clinical-stage US biotech developing iPSC-derived off-the-shelf NK and T-cell cancer immunotherapies — directly comparable allogeneic iPSC platform play, with similar manufacturing-scalability thesis and pharma partnership model.
- Century Therapeutics: Clinical-stage iPSC-derived allogeneic cell therapy developer (iNK and iT cells) for oncology — closely comparable to TreeFrog's iPSC platform approach, allogeneic positioning, and partnership-oriented strategy.
- Aspen Neuroscience: Clinical-stage company developing autologous iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease — directly competes with TFG-001 in indication, though TreeFrog takes an allogeneic 3D-microtissue approach.
- Cynata Therapeutics: Clinical-stage Australian biotech developing iPSC-derived MSC therapies for inflammatory and degenerative diseases — comparable iPSC platform with out-licensing/partnership approach, though focused on MSCs rather than neural microtissues.
Emerging players
- Notch Therapeutics: Clinical-stage iPSC-derived T-cell therapy developer with a focus on scalable manufacturing of engineered immune cells — comparable iPSC-derived allogeneic cell therapy positioning to TreeFrog's C-Stem platform applications in immuno-oncology.
- Shoreline Biosciences: iPSC-derived allogeneic NK cell therapy developer partnered with multiple pharma companies (Kite/Gilead, BeiGene) — comparable partnership-driven iPSC platform model to TreeFrog's C-Stem out-licensing strategy.
- Cellares: Cell therapy manufacturing automation company (Cell Shuttle platform) — adjacent competitor in the cell therapy manufacturing scale-up space where TreeFrog's C-Stem also operates; competes for the same pharma CDMO/partnership wallet.
- Cytovia Therapeutics: Clinical-stage iPSC-derived NK cell therapy developer for oncology — comparable iPSC-derived allogeneic immuno-oncology cell therapy approach to several of TreeFrog's C-Stem partnership programs.
- Pluristem Therapeutics: Cell therapy company developing placenta-derived stem cell therapies with proprietary 3D bioreactor manufacturing platform — comparable regenerative medicine positioning and manufacturing-platform thesis to TreeFrog, though using adult rather than iPSC-derived cells.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TreeFrog Therapeutics social profiles
Digital presenceTreeFrog Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TreeFrog Therapeutics leadership team
Management profileNumber of profiles
Profiles16 records
TreeFrog Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TreeFrog Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TreeFrog Therapeutics
What does TreeFrog Therapeutics do?
TreeFrog Therapeutics develops and out-licenses C-Stem™, a proprietary biomimetic 3D cell culture and encapsulation technology platform that enables industrial-scale, GMP-compliant manufacturing of iPSC-derived cell therapies (up to 15 billion cells per batch in 10L bioreactors). The company also internally develops a proprietary pipeline of regenerative medicine cell therapies, with its lead program TFG-001 (3D neural microtissue for Parkinson's disease, first-in-human trial planned for 2026) and a discovery-stage liver disease program.
Is TreeFrog Therapeutics a public or private company?
TreeFrog Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was TreeFrog Therapeutics founded?
TreeFrog Therapeutics was founded in 2018. It employs 101 to 250 people.
Where is TreeFrog Therapeutics based?
TreeFrog Therapeutics is headquartered in Bordeaux, France, in the Europe region.
How does TreeFrog Therapeutics make money?
Three revenue lines are on record. Proprietary Cell Therapy Pipeline is the primary driver. The others are C-Stem™ Technology Licensing and strategic Partnerships & Co-development.
Who are TreeFrog Therapeutics's main competitors?
Direct peers on record are BlueRock Therapeutics, Fate Therapeutics, Century Therapeutics, Aspen Neuroscience and Cynata Therapeutics. Emerging players are Notch Therapeutics, Shoreline Biosciences, Cellares, Cytovia Therapeutics and Pluristem Therapeutics.
Does TreeFrog Therapeutics have an API?
No public API is recorded for TreeFrog Therapeutics.
What industry is TreeFrog Therapeutics in?
TreeFrog Therapeutics's product category is Regenerative Medicine Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.